Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

In Brief

Executive Summary

Further delay for Prevnar 13: FDA has not yet completed its review of Pfizer's Prevnar 13 vaccine for pneumococcal disease and therefore the review will continue beyond the Dec. 30 user fee deadline. It's not clear how much longer the review will take and there was no explanation for the delay, but there was no indication that additional information was sought, according to the drug maker's Dec. 30 statement. The vaccine is under priority review and FDA already used its one-time extension of the user fee period to move the original action date of Sept. 30 to the December date, after additional manufacturing data was submitted. An FDA advisory committee voted 10 to 1 on Nov. 18 to recommend the product, although the panel did not endorse a broad claim for otitis media (1"The Pink Sheet," Nov. 23, 2009). European marketing authorization was granted on Dec. 11

You may also be interested in...



Shire Prepares To Compete With Genzyme In Gaucher Market With 15% Price Discount

During its 2009 earnings call, the company also reported significant sales increase for its Replagal drug for Fabry disease.

Pfizer Pulls Lyrica sNDA As Adjunct For Anxiety Disorder

The FDA gave the pregabalin sNDA for generalized anxiety disorder monotherapy a "complete response" in December for insufficient data.

Pfizer Halts Phase III Figitumumab Trial In NSCLC But Forges On With Other Studies

Insulin growth factor-1 receptor inhibitor is one of Pfizer's lead oncology candidates, but the company is not throwing in the towel on figitumumab yet.

Related Content

Topics

UsernamePublicRestriction

Register

PS051802

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel